熱門資訊> 正文

免疫工程在治疗胰腺癌的孤儿药物指定中崛起

2024-10-15 21:04

Immuneering Corporation (NASDAQ:IMRX) shares up 24.5% premarket after it announced that the U.S. FDA has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer.
IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including pancreatic cancer.
Source: Press Release

More on Immuneering, Teva Pharmaceutical, etc.

Teva Pharmaceutical Industries Limited (TEVA) Bank of America Global Healthcare Conference (Transcript)
Cheap Teva Stock Should Reward Patient Investors
Teva Pharmaceutical Industries Limited (TEVA) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Teva agrees to pay $425M to settle Copaxone kickback case: DOJ
TEVA applications for Prolia biosimilar accepted by FDA, EMA

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。